NOTE F12 Depreciation, amortization and impairments
- Index
- 12 NOTE F12 Depreciation, amortization and impairments
- 13 NOTE F13 Other non-operating and non-cash items
- 14 NOTEF14 Income taxes
- 15 NOTE F15 Changes in working capital
- 16 NOTE F16 Changes in provisions
- 17 NOTE F17 Cash flows from investing activities – acquisition/disposal of assets and investments
- 18 NOTE F18 Equity
- 19 NOTE F19 Other cash flows from financing activities
- 20 NOTE F20 Cash flow from discontinued operations
In 2017 total depreciation, amortization and impairment losses amount to €1,152 million, of which:
- straight-line depreciation and amortization of €954 million for continuing operations including:
- cost of goods sold (€552 million),
- administrative and commercial costs (€106 million),
- research and development costs (€55 million),
- other (€241 million), including €206 million for PPA amortization (see note F4 Other operating gains and losses),
- net impairment loss of €100 million for continuing operations (see note F5 Results from portfolio management and reassessments, legacy remediation and major litigations), and
- €98 million for discontinued operations, including €69 million for straight-line depreciation and amortization (including PPA) related to Polyamides.
In 2016 total depreciation, amortization and impairment losses amounted to €1,302 million, of which:
- straight-line depreciation and amortization of €930 million for continuing operations including:
- cost of goods sold (€541 million),
- administrative and commercial costs (€101 million),
- research and development costs (€50 million),
- other (€238 million), including €214 million for PPA amortization (see note F4 Other operating gains and losses),
- net impairment loss of €143 million for continuing operations (see note F5 Results from portfolio management and reassessments, legacy remediation and major litigations),
- impairment loss of Solvay Indupa of €63 million, and
- €165 million for discontinued operations, including €95 million for straight-line depreciation and amortization (including PPA) related to Polyamides.